2-(4-methoxyphenyl)-N-(2-(2-methyl-1H-imidazol-4-yl)thiophen-3-yl)acetamide | 1239464-57-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-methoxyphenyl)-N-(2-(2-methyl-1H-imidazol-4-yl)thiophen-3-yl)acetamide
• 英文别名: 2-(4-methoxyphenyl)-N-[2-(2-methyl-1H-imidazol-5-yl)thiophen-3-yl]acetamide
• CAS: 1239464-57-3
• 化学式: C₁₇H₁₇N₃O₂S
• 分子量: 327.407
• InChiKey: LFLTYJDEZSLZGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  95.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-(4-Methoxyphenyl)-N-(2-(2-methyl-1-trityl-1H-imidazol-4-yl)thiophen-3-yl)acetamide 以 三氟乙酸 为溶剂， 反应 1.0h， 以to yield 2-(4-methoxyphenyl)-N-(2-(2-methyl-1H-imidazol-4-yl)thiophen-3-yl)acetamide的产率得到2-(4-methoxyphenyl)-N-(2-(2-methyl-1H-imidazol-4-yl)thiophen-3-yl)acetamide
  参考文献：
  名称：

  Inhibitors of Jun N-terminal kinase

  摘要：

  本公开提供具有以下式子结构的c-Jun N末端激酶（JNK）抑制剂：或其盐或溶剂，其中环A，Ca，Cb，Z，R5，W和Cy在此定义。本公开还提供包括本公开化合物的药物组合物，以及使用本公开化合物和组合物的方法，例如在治疗和预防各种疾病中，如阿尔茨海默病。

  公开号：

  US09073891B2

文献信息

• [EN] INHIBITORS OF JUN N-TERMINAL KINASE<br/>[FR] INHIBITEURS DE L'ENZYME JUN N-TERMINAL KINASE
  申请人：ELAN PHARM INC

  公开号：WO2010091310A1

  公开（公告）日：2010-08-12

  The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula (I): or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.

  本公开提供了具有以下结构的c-Jun N-末端激酶（JNK）抑制剂（I）的结构，或其盐或溶剂化物，其中环A，Ca，Cb，Z，R5，W和Cy在此处定义。本公开还提供了包括本公开化合物的药物组合物，以及制备和使用本公开化合物和组合物的方法，例如在治疗和预防各种疾病，如阿尔茨海默病。
• INHIBITORS OF JUN N-TERMINAL KINASE
  申请人：SHAM Hing L.

  公开号：US20130072494A1

  公开（公告）日：2013-03-21

  The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, C a , C b , Z, R 5 , W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.

  本公开提供了具有以下结构的c-Jun N端激酶（JNK）抑制剂： 或其盐或溶剂，其中环A、Ca、Cb、Z、R5、W和Cy在此被定义。本公开还提供了包括本公开化合物的药物组合物以及制备和使用本公开化合物和组合物的方法，例如，在治疗和预防各种疾病，如阿尔茨海默病中使用。
• Inhibitors of Jun N-Terminal Kinase
  申请人：Sham Hing L.

  公开号：US20100331335A1

  公开（公告）日：2010-12-30

  The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, C a , C b , Z, R 5 , W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.

  本公开提供抑制c-Jun N-末端激酶（JNK）的抑制剂，其结构符合以下公式：其中环A、Ca、Cb、Z、R5、W和Cy在此定义。本公开还提供包括本公开化合物的药物组合物以及制备和使用本公开化合物和组合物的方法，例如在治疗和预防各种疾病，如阿尔茨海默病中的应用。
• Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK
  作者：Roy K. Hom、Simeon Bowers、Jennifer M. Sealy、Anh P. Truong、Gary D. Probst、Martin L. Neitzel、R. Jeffrey Neitz、Larry Fang、Louis Brogley、Jing Wu、Andrei W. Konradi、Hing L. Sham、Gergely Tóth、Hu Pan、Nanhua Yao、Dean R. Artis、Kevin Quinn、John-Michael Sauer、Kyle Powell、Zhao Ren、Frédérique Bard、Ted A. Yednock、Irene Griswold-Prenner

  DOI：10.1016/j.bmcl.2010.10.066

  日期：2010.12

  From high throughput screening, we discovered compound 1, the prototype for a series of disubstituted thiophene inhibitors of JNK which is selective towards closely related MAP kinases p38 and Erk2. Herein we describe the evolution of these compounds to a novel class of thiophene and thiazole JNK inhibitors that retain favorable solubility, permeability, and P-gp properties for development as CNS agents for treatment of neurodegeneration. Compound 61 demonstrated JNK3 IC(50) = 77 nM and retained the excellent broad kinase selectivity observed for the series. (C) 2010 Elsevier Ltd. All rights reserved.
• TREATMENT OF FIBROTIC DISORDERS WITH JUN N-TERMINAL KINASE INHIBITORS
  申请人：Imago Pharmaceuticals, Inc.

  公开号：EP3509586A1

  公开（公告）日：2019-07-17